Molecular Imaging Probe Development

摘要： 分子成像对肿瘤学的影响涵盖了临床管理的各个方面，包括早期 检测，指导靶向治疗和生物标志物的临床前开发， 疾病和监测对治疗剂的反应。分子影像学的应用可以显著降低 通过允许准确的患者治疗分层，开发新疗法所产生的成本 并允许对体内治疗的生物学反应进行非侵入性连续评估。但 对于分子成像剂的开发和转化已经出现了显著的瓶颈， 特别是用于正电子发射断层摄影术（PET探针）的那些。目前的限制， 用于PET的靶向分子成像剂的开发和转化包括但不限于： 用于靶向配体鉴定和成像剂的复合物设计、合成和筛选方法 发展 因此，显然越来越需要具有广泛研究的杰出实验室科学家 在生物成像研究领域的经验，更具体地说，在豪斯纳博士放射化学和 分子成像PET探针的探针优化。豪斯纳博士等科学家提供了连续性， 稳定性和详细的科学知识对学生和受训者来说远远超出了技术人员的能力， 来维持分子成像研究事业。这次资助是一个很好的机会，以表彰博士 豪斯纳的贡献，不仅对萨克利夫实验室，而且对分子成像研究。它还将 使他能够发展一个更明确和稳定的职业道路，以追求基础，转化和 在Sutcliffe研究计划中进行临床分子成像研究，而无需成为 独立调查员Hausner博士将继续支持靶向分子成像的发展 Sutcliffe实验室的癌症检测试剂，更具体地说， 基于肽的分子成像剂的药代动力学。分子显像剂在发展中 Sutcliffe实验室支持在分子生物学中心进行的小鼠和非人类灵长类动物的临床前研究。 和基因组成像，以及通过加州大学戴维斯分校综合癌症中心和 放射科。Sutcliffe博士是主要的支持单位主任，他将继续与 豪斯纳计划，指导和监督拟议的研究。

ABSTRACT: The impact of Molecular Imaging on oncology encompasses all aspects of clinical management including early detection, guiding the preclinical development of targeted therapeutics and biomarkers, assisting staging of disease and monitoring response to therapeutics. Utilization of Molecular Imaging can significantly decrease the costs incurred with the development of new therapies by allowing accurate patient treatment stratification and allowing the non-invasive serial assessment of the biological response to treatment in vivo. However, a significant bottleneck has emerged for the development and translation of molecular imaging agents, specifically those utilized for positron emission tomography (PET probes). Current limitations for the rapid development and translation of targeted molecular imaging agents for PET include but are not limited to; the complex design, synthesis and screening approaches for both targeted ligand identification and imaging agent development. As such there is clearly a growing need for exceptional laboratory-based scientists with extensive research experience in the field of bioimaging research, more specifically in the case of Dr Hausner radiochemistry and probe optimization for molecular imaging PET probes. Scientists such as Dr Hausner provide the continuity, stability and detailed scientific knowledge to students and trainees far beyond that of a technician and are vital to sustain the molecular imaging research enterprise. This funding is an excellent opportunity to recognize Dr Hausner’s contributions, not only to the Sutcliffe laboratory but also to molecular imaging research. It will also allow him to develop a more defined and stable career path to pursue research in basic, translational, and clinical molecular imaging research within the Sutcliffe research program without the pressure of becoming an independent investigator. Dr Hausner will continue to support the development of targeted molecular imaging agents for cancer detection in the Sutcliffe laboratory and more specifically focus on improving the pharmacokinetics of peptide based molecular imaging agents. Molecular imaging agents under development in the Sutcliffe laboratory support pre-clinical studies in mice and non-human primates at the Center for Molecular and Genomic Imaging, as well as clinical studies through the UC Davis Comprehensive Cancer Center and the Department of Radiology. Dr Sutcliffe is the primary support Unit Director who will continue to work with Dr Hausner to plan, direct and monitor the proposed research.